Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?

被引：0

作者：

Watson, T ^{[1
]}

Lip, GYH ^{[1
]}

机构：

[1] Univ Birmingham, City Hosp, Dept Med, Birmingham B18 7QH, W Midlands, England

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2006年 / 60卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：253 / 255

页数：3

共 27 条

[21] Antithrombotic therapy in vaivular heart disease - Native and prosthetic [J].

Salem, DN ;

Stein, PD ;

Al-Ahmad, A ;

Bussey, HI ;

Horstkotte, D ;

Miller, N ;

Pauker, SG .

CHEST, 2004, 126 (03) :457S-482S

[22] PATIENT PREFERENCES FOR STROKE OUTCOMES [J].

SOLOMON, NA ;

GLICK, HA ;

RUSSO, CJ ;

LEE, J ;

SCHULMAN, KA .

STROKE, 1994, 25 (09) :1721-1725

[23] Recent national patterns of warfarin use in atrial fibrillation [J].

Stafford, RS ;

Singer, DE .

CIRCULATION, 1998, 97 (13) :1231-1233

[24] Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK [J].

Stewart, S ;

Murphy, N ;

Walker, A ;

McGuire, A ;

McMurray, JJV .

HEART, 2004, 90 (03) :286-292

[25]

THRALL G, IN PRESS AM J MED

[26] ATRIAL-FIBRILLATION AS AN INDEPENDENT RISK FACTOR FOR STROKE - THE FRAMINGHAM-STUDY [J].

WOLF, PA ;

ABBOTT, RD ;

KANNEL, WB .

STROKE, 1991, 22 (08) :983-988

[27]

1993, J STROKE CEREBROVASC, V3, P181

← 1 2 3 →